| [1] |
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 12 7(12): 2893-917.
|
| [2] |
Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease[J]. Lancet Oncol, 2004, 5(11): 655-63.
|
| [3] |
Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients[J]. Ann Oncol, 2007, 18(10): 1660-5.
|
| [4] |
Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systematic review of the effi cacy and safety of anticoagulants as cancer treatment:impact on survival and bleeding complications[J]. Cancer, 2007, 110(5): 1149-61.
|
| [5] |
Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis[J]. Am J Cancer, 1938, 34(4):566-85.
|
| [6] |
Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism[J]. N Engl J Med, 20 00, 343(25): 1846-50.
|
| [7] |
Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer[J]. Clin Cancer Res, 2007, 13(10): 2870-5.
|
| [8] |
Bloomston M, Zhou JX, Rosemurgy AS, et al. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples[J]. Cancer Res, 2006, 66(5): 25 92-9.
|
| [9] |
Guo Q, Zhang B, Dong X, et al. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor[J]. Pancreas, 2009, 38(3): e75-9.
|
| [10] |
Wahrenbrock M, Borsig L, Le D et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas[J]. J Clin Invest, 2003, 112(6): 853-62.
|
| [11] |
Rudroff C, Seibold S, Kaufmann R, et al. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro[J]. Clin Exp Metastasis, 2002, 19 (2): 181-9.
|
| [12] |
Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study[J]. Arch Intern Med, 2000, 160(6): 809-15.
|
| [13] |
Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer[J]. N Engl J Med, 2003, 34 9(2): 146-53.
|
| [14] |
Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer[J]. J Clin Oncol, 2007, 25(34): 5490-505.
|
| [15] |
von Delius S, Ayvaz M, Wagenpfeil S, et al. Effect of lowmolecular- weight heparin on survival in patients with advanced pancreatic adenocarcinoma[J]. Thromb Haemost, 2007, 98(2): 43 4-9.
|
| [16] |
Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the effi cacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer[J]. J Surg Oncol, 20 07, 95(6): 507-12.
|
| [17] |
Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer[J]. Eur J Cancer, 2012, 48(9): 1283-92.
|
| [18] |
Riess H, Pelzer U, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.[J]. ASCO Meeting Abstracts, 2010, 28(suppl 15):Abstract 4033.
|
| [19] |
van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer[J]. J Clin Oncol, 2011, 29(15): 20 71-6.
|
| [20] |
Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study[J]. Lancet Oncol, 2009, 10(10): 943-9.
|
| [21] |
Agnelli G, George DJ, Fisher W, et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study[J]. ASCO Meeting Abstracts, 20 11, 29(suppl 18): Abstract A9014.
|
| [22] |
Mackman N. Triggers, targets and treatments for thrombosis[J]. Nature, 2008, 451(7181): 914-8.
|
| [23] |
Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival[J]. J Clin Oncol, 2009, 27(29): 4902-11.
|
| [24] |
Vignoli A, Marchetti M, Russo L, et al. LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells[J]. Cancer Invest, 2011, 29(2): 153-61.
|
| [25] |
Mousa SA, Petersen LJ. Anti-cancer properties of low-molecularweight heparin: preclinical evidence[J]. Thromb Haemost, 2009, 10 2(2): 258-67.
|
| [26] |
Debergh I, Van Damme N, Pattyn P, et al. The low-molecularweight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model[J]. Br J Cancer, 2010, 10 2(5): 837-43.
|
| [27] |
Collen A, Smorenburg SM, Peters E, et al. Unfractionated and low molecular weight heparin affect fi brin structure and angiogenesis in vitro[J]. Cancer Res, 2000, 60(21): 6196-200.
|
| [28] |
Khorana AA, Sahni A, Altland OD, et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight[J]. Arterioscler Thromb Vasc Biol, 2003, 23(11): 21 10-5.
|
| [29] |
Cao G, Wu JX, Wu QH. Low molecular weight heparin suppresses lymphatic endothelial cell proliferation induced by vascular endothelial growth factor C in vitro[J]. Chin Med J (Engl), 2009, 12 2(13): 1570-4.
|
| [30] |
Zwicker JI. Predictive value of tissue factor bearing microparticles in cancer associated thrombosis[J]. Thromb Res, 2010, 125 Suppl 2: S89-91.
|
| [31] |
Ettelaie C, Fountain D, Collier M E, et al. Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-kappaB[J]. Biochim Biophys Acta, 2011, 1812(12): 15 91-600.
|
| [32] |
Amirkhosravi A, Meyer T, Amaya M, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis[J]. Semin Thromb Hemost, 2007, 33(7): 643-52.
|
| [33] |
Ichikawa J, Cole HA, Magnussen RA, et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma[J]. Cancer, 2012, 118(9): 2494-506.
|
| [34] |
Laubli H, Borsig L. Selectins promote tumor metastasis[J]. Semin Cancer Biol, 2010, 20(3): 169-77.
|
| [35] |
Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity[J]. Clin Cancer Res, 2005, 11 (19 Pt 1): 7003-11.
|
| [36] |
Simonis D, Christ K, Alban S, et al. Affinity and kinetics of different heparins binding to P- and L-selectin[J]. Semin Thromb Hemost, 2007, 33(5): 534-9.
|
| [37] |
Streiff MB,National Comprehensive Cancer Center Network. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients[J]. Thromb Res, 2010, 125 Suppl 2: S128-33.
|
下载:
